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1  | BACKGROUND AND OBJEC TIVES
Airborne	allergens	 in	 living	and	working	environments	play	an	 im‐
portant	 role	 in	eliciting	 type	1	allergic	disorders,	 including	asthma	
and	hay	 fever.	Allergies	belong	 to	 the	 so‐called	noncommunicable	
diseases	which	have	dramatically	risen	with	industrialization	and	ur‐
banization	 worldwide.1,2	 Nearly	 600	 asthma‐causing	 occupational	
agents	 have	 been	 identified,	 of	 which	 two	 thirds	 are	 airway	 sen‐
sitizers.3	Every	year	new	allergic	agents	are	 identified	at	 changing	





















presently	not	 known.	Also	 less	exposure	 to	microbial	 load	and	di‐
versity	in	both	childhood	and	adulthood	due	to	the	global	increase	
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tiated	 from	 type	4	allergic	 contact	dermatitis,	 not	 covered	by	 this	
guideline.
The	 diagnostic	 measurement	 of	 specific	 IgE	 (sIgE)	 is	 often	 a	
major	step	in	identifying	the	precise	cause(s)	of	respiratory	allergy.	
However,	 only	 a	 limited	 number	 of	 allergen‐sIgE	 are	 commer‐
cially	available,	especially	in	the	occupational	field.	This	necessitates	














tics	 of	 exposure‐related	 type	 1	 respiratory	 allergic	 diseases.	 This	
document	 represents	 international	 practical	 statements	 with	 the	
primary	objective	to	provide	an	overview	on	available	methods	re‐
quired	for	state‐of‐the‐art	clinical	diagnostic	purposes	and	for	mak‐
ing	 recommendations	 for	 clinical	 practice.	 This	 document	 focuses	
on	diagnosis	of	respiratory	allergic	disorders	caused	by	occupational	
and/or	environmental	industrial	agents,	but	may	also	be	applied	to	
related	 skin	 allergic	 disorders.	 The	 recommendations	 include	 ex‐
posure	assessment	and	in‐house	in	vitro	testing	with	commercially	












2  | CLINIC AL PIC TURES OF T YPE I 











There	 is	evidence	 that	 type	1	allergies	caused	by	 industrial	 al‐







F I G U R E  1  Asthma	between	
population	discrepancies.	Figure	adapted	
from:	ISAAC	(1998),	Lancet	351:1225‐32
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rather	 seldom	described	and	presumably	 rare.	 Ingredients	 such	as	
enzymes	in	fragrances,	cosmetic	products,	detergents,	or	food	(the	
latter	includes	processing	at	home)	are	some	of	the	examples.4,15,16
3  | C AUSAL AGENTS
Agents	that	cause	allergic	WRA	and/or	allergic	occupational	rhinitis	en‐
compass	more	than	400	natural	agents	and	synthetic	chemicals.	They	














from	 laboratory	 animals	 and	 insects,	 enzymes,	 colophony	 fluxes,	
solders,	 wood	 dusts,	 natural	 rubber	 latex,	 acrylates,	 and	 glutaral‐
dehyde.	Following	 sensitization,	workers	with	OA	may	develop	an	
asthmatic	attack	to	very	low	exposures	to	the	sensitizer.	The	extent	
of	 airway	 responsiveness	 may	 diminish	 away	 from	 exposure,	 but	
usually	increases	with	re‐exposure	to	the	sensitizer.
4  | DIAGNOSTIC ME A SUREMENT OF sIgE 
A S THE MA JOR STEP IN IDENTIF YING THE 
PRECISE C AUSE OF RESPIR ATORY ALLERGY






























three‐steps,	 solid	 phase,	 noncompetitive	 binding,	 immune‐metric	
(labeled	antibody)	chemistry,	combined	with	a	third	step,	that	is,	en‐
zyme‐substrate	 color,	 florescence,	 or	 luminescence	 development.	
Allergen‐sIgE	antibodies	are	bound	in	the	first	incubation	to	a	solid	
phase	allergen	and	then	bound	IgE	is	detected	in	a	second	reaction	




the	World	Health	Organization	 human	 IgE	 reference	 preparations	
(note	WHO	recently	depleted	75/502	preparation	is	replaced	with	
third	 standard:	 11/234).	 This	 allows	 interpolation	 of	 IgE	 antibody	









being	 replaced	with	 Falcon).	Other	 IgE	 assays	with	 a	 limited	mar‐
ket	share	include	Thabest	IgE	(Visual	Diagnostics),	Optigen	(Hitachi	
Chemical	Diagnostics),	and	ALLERG‐O‐LIQ	(Fooke	laboratories).
Each	 of	 the	 principal	 auto	 analyzers	 has	 comparable	 perfor‐
mance	 parameters,	 which	 have	 to	 be	 described	 and	 cleared	 by	




Studies	 have	 compared	 the	 three	main	 sIgE	 assays	 and	 all	 re‐
ported	different	levels	of	IgE	antibody	for	any	given	specificity.24‐26 








standardization	 to	 the	 WHO	 human	 IgE	 reference	 preparation,	
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revealed	that	there	were	disparate	results	in	four	of	the	six	labora‐
tories.28	 This	 highlights	 the	need	 for	 laboratories	 to	 participate	 in	
quality	assurance	schemes	(eg,	CLIA,	ISO	17025)	and	to	make	those	
results	available	to	their	clients.
Historically,	 0.35	 kUA/l	 of	 allergen‐sIgE	was	 considered	 to	 be	
the	cutoff	point	where	an	individual	was	considered	as	a	threshold	











IgE	 levels	 in	 the	context	of	 the	clinical	history,	 rather	 than	have	a	
defined	 cutoff	 point.29	 See	 Supporting	 information	 (page	 S18)	 for	
more	details.
It	 is	 important	 to	 understand	 that	 the	 presence	 of	 sIgE	 is	 an	
indicator	 of	 sensitization,	 it	 is	 not	 proof	 of	 allergic	 disease	 and	 is	





the	patient	 appropriately	 and	encourage	 improvement	of	environ‐
mental	control	measures	within	the	workplace.
















4.2 | Occupational allergens are categorized as 
either high or low molecular weight
sIgE	assays	are	useful	to	demonstrate	IgE‐mediated	sensitization	to	










ing	 to	 the	 conjugate	 preparation	 conditions.35,36	One	 of	 the	 diffi‐
culties	with	measuring	 sIgE	 to	 LMW	allergens	 (including	 products	
acting	 as	 haptens37,38)	 is	 that	 there	 are	 no	 standardized	 protocols	
for	the	preparation	of	protein‐LMW	allergen	conjugates	and,	char‐
acterization	of	 the	 resultant	 protein	hapten	 complex	 can	be	 tech‐
nically	challenging	and	complex.	There	were	various	approaches	to	
bind	LMW	agents	such	as	acid	anhydrides,7,39	glutaraldehyde,40 or 

















grass	 pollen.45	 This	 suggests	 that	 in	 some	patients,	 isocyanate	 in‐




bumin‐conjugate	 is	 unlikely	 to	be	 a	 causative	 factor	 in	 the	patho‐
mechanism	of	western	red	cedar	asthma,	suggesting	that	this	may	
also	be	a	non‐IgE‐mediated	disease,	at	least	in	some	patients.	Animal	


















4.4 | The need for assay standardization
At	present	there	are	no	standard	operating	procedures	for	conduct‐
ing	“in‐house”	assays.33	Current	FDA	guidance	regulations,	regard‐
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4.5 | Early biomarkers of allergic sensitization, 










5  | OUTCOME OF THE META‐ANALYSIS 
AND RE VIE W PERTINENT QUESTIONS
5.1 | What are the sIgE test performances for high 
molecular weight allergens?
The	 aforementioned	 meta‐analysis	 of	 studies	 including	 asthmatic	
subjects	exposed	to	various	occupational	HMW	agents	found	that	
specific	 IgE	 determination	 provided	 a	 sensitivity	 of	 74%	 [95%	 CI	
66%‐80%],	as	compared	with	specific	inhalation	challenge	or	serial	












allergens	 ranged	 from	 72%	 [95%	 CI	 42%‐90%]	 for	 cellulase,	 0.79	
[95%	CI	65%‐88%]	for	wheat,	0.84	[95%	CI	65%‐94%]	for	rye	to	0.88	
[95%	CI	42%‐99%]	for	latex.33
















Vandenplas	 et	 al31	 found	 that	 the	 sum	 of	 sIgE	 concentrations	
against	the	recombinant	allergens	of	Hevea brasiliensis	(rHev	b5)	and	












residue.	For more information, see: Hettick, J et al Xenobiotica. 2017 Jul 21:1‐11; Nayak, A et al Toxicol Sci. 2014 Aug 1;140(2):327‐37; Hettick, J et 
al Anal Biochem. 2012 Feb 15;421(2):706‐11; Wisnewski, A et al Anal Biochem. 2010 May 15;400(2):251‐8
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respectively).	 Combining	 positive	 sIgE	 results	 for	 the	NRL	 extract	
and	the	recombinant	allergen	components	rHev	b	5,	6.01,	6.02,	and	
11	provided	similar	AUC	(0.84‐0.85)	and	Youden	 index	 (0.61‐0.65)	
values	 (data	not	detailed),	but	did	not	 improve	 the	diagnostic	per‐
formance.	 Nevertheless,	 measurement	 of	 sIgE	 antibodies	 against	
the	tested	panel	of	recombinant	latex	allergen	components	did	not	
improve	 the	negative	predictive	value	of	 immunological	 testing	as	
none	of	the	subjects	with	positive	SIC	and	a	negative	IgE	against	the	
whole	latex	extract	showed	IgE	reactivity	to	allergen	components.






5.3 | What are the sIgE test performances for low 
molecular weight allergens?
For	LMW	the	preparation	conditions	can	greatly	affect	the	degree	














20%	with	 comparable	 specificity	 (personal	 communication).	Meta‐
analysis	provided	21%	[95%	CI	14%‐31%]	and	94%	[95%	CI	88%‐97%])	
for	pooled	pairs	of	 sensitivity	and	specificity.33	Pooled	sensitivities	
of	 single	 diisocyanates	HDI,	 TDI,	 and	HDI	 ranged	 from	 21%‐42%.	
Sensitivity	for	acid	anhydrides	was	exceptionally	high	with	81%	[95%	
CI	46%‐95%],	but	the	estimation	was	based	on	few	results33.
6  | ALLERGEN E XPOSURE A SSESSMENT
An	 important	 aspect	 in	 the	management	 and	 diagnosis	 of	 type	 1	
allergic	 disorders	 is	 the	 knowledge	 of	 the	 environmental	 levels	 of	
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job	exposure	matrices,	direct	 sampling	of	 the	air	 and	on	 skin,	 and	
biomonitoring.
6.1 | Air sampling methods and databases
Heederik	 et	 al60	 thoroughly	 addressed	 the	 topic	 of	workplace	 ex‐
posure	 sampling,	 analyses,	 assessment	 strategies,	 and	 data	 inter‐






















as	 guiding	 documents:	 Purpose	 and	 Scope,	 Development	 and	
Evaluation	 of	 Methods,	 Measurement	 Uncertainty	 and	 NIOSH	
Method	 Accuracy	 Range,	 General	 Considerations	 for	 Sampling	
Airborne	 Contaminants,	 Factors	 Affecting	 Aerosol	 Sampling,	
Sampling	and	Characterization	of	Bioaerosols,	Filter	Pore	Size	and	
Aerosol	Sample	Collection,	Measurement	of	Fibers,	and	Sampling	
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contain	 many	 methods	 for	 the	 more	 common	 ones.	 Methods	















































































































TA B L E  2   (Continued)
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low molecular weight agents is mostly performed with help of ambi‐
ent‐ and biomonitoring methods.60
For	details	see60	and	Supporting	information	(page	S23).
7  | INTEGR ATED DIAGNOSTIC 
APPROACH FOR OCCUPATIONAL AND 
ENVIRONMENTAL INDUSTRIAL ALLERGENS
Details	are	given	in	Figure	4	and	in	the	Figure	S2.
















allows	 the	 risk	 of	 allergic	 disorders	 to	 be	 estimated.	 Surveillance	
of	high	 risk	 subjects	 (eg,	 those	with	high	 level	of	 sIgE	antibodies)	
and	individuals	in	“at‐risk”	sites,	especially	workplaces,	are	recom‐
mended	 in	order	 to	 take	appropriate	preventive	measures	and	 to	
optimize	medication.
For	a	broader	view	of	this	items	see	Supporting	information,	sec‐
tion	Points to be emphasized and prospective.
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